contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


guard-therapeutics-provides-update-on-strategic-review

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.

Guard Therapeutics

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.The Company has...

<div class="mfn-preamble"><p><strong>Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.</strong></p></div><div class="mfn-body"><p>The Company has now completed the overarching exploratory work, in accordance with the press release issued on 5 February, and has identified a number of potential counterparties that are assessed as possibly being suitable candidates for a merger or a reverse takeover. Guard Therapeutics intends to initiate more in-depth discussions with prioritized parties in the near term.<br>&nbsp;<br>The Company’s objective is to carry out due diligence work during the second quarter of 2026 and thereafter communicate additional details regarding the continued process. However, it cannot be ruled out that the review may not result in any transaction or other strategic outcome.<br>&nbsp;<br>If no strategic alternatives materialize within a reasonable period of time, the Board of Directors intends to recommend delisting from Nasdaq First North Growth Market and voluntary liquidation, whereby available cash would be distributed to shareholders. Decisions regarding any potential merger, reverse takeover, delisting or liquidation will be made by shareholders at a future general meeting.<br>&nbsp;<br>Guard Therapeutics undertakes no obligation to provide further information until the Board of Directors has made final decisions, subject to applicable regulations.</p></div><div class="mfn-footer mfn-contacts mfn-5da762a72d6c"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p><strong>Tobias Agervald,&nbsp;CEO</strong><br>Telephone:&nbsp;+46 8&nbsp;670 65 51<br>E-mail: info@guardtherapeutics.com&nbsp;</p></div><div class="mfn-footer mfn-about mfn-33a07df364dd"><p><strong class="mfn-heading-1">About Guard Therapeutics</strong></p><hr><p>Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with a large unmet medical need, focusing on different forms of kidney disease. The company’s candidate drugs are based on the endogenous protein alpha-1-microglobulin (A1M). Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm (ticker: GUARD).</p><p>Certified Adviser is Redeye Nordic Growth AB, <a href="https://www.redeye.se/advisory/certified-adviser" rel="noopener">Certified Adviser - Redeye</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/234eab3e-c0fc-4b78-8d7f-aa8b6d78aad2/guard-therapeutics-provides-update-on-strategic-review.pdf" rel="noopener">Guard Therapeutics provides update on strategic review</a></p></div>